Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI)   APRIL 2016 , Volume 15 , Number 2; Page(s) 112 To 121.
 
Paper: 

EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH DERMATOPHAGOIDES PTERONYSSINUS: A REAL-LIFE STUDY

 
 
Author(s):  VESNA TOMIC SPIRIC, DENISA DIZDAREVIC, SLAVENKA JANKOVIC, LIDIJA BURAZER, ALEKSANDRA BARAC*, JASNA BOLPACIC, VOJISLAV DJURIC, ALEKSANDRA PERIC POPADIC, ALEKSANDRA ALEKSIC
 
* INSTITUTE FOR MICROBIOLOGY AND IMMUNOLOGY, FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE, DR SUBOTICA 1, 11000, BELGRADE, SERBIA
 
Abstract: 

Sublingual allergen immunotherapy (SLIT) is considered to be safer and more convenient than subcutaneus immunotherapy. SLIT trials with house dust mites involving patients with allergic rhinitis (AR) and asthma reported discordant results. The aim of the study was to investigate the clinical efficacy and safety of SLIT with Dermatophagoides pteronyssinus (D.pt) extract produced in Serbia and patient’s satisfaction through open-label trial.
Adult patients with allergic rhinitis were randomized into two groups: one received drugs and SLIT, while other received only drugs. Symptom score (SS), medication score (MS) and cumulative score (CS), skin prick tests (SPT) and serum level of D. pt specific IgE were assessed. One year after, the patients were re-evaluated.
In total, 61 patients were enrolled in the study, but 52 of them were analyzed at the end of the year. CS (29.3%, p<0.001) and MS (54.3%, p<0.05) reduced significantly in the SLIT group. There was a significant improvement of MS and CS in the SLIT compared to control group (p<0.001 and p<0.05 respectively). There was no significant improvement of SS as well as specific slgE. Patients in the SLIT group were more satisfied with treatment (p<0.001). The incidence of mild adverse reaction was 38.4%. Specific lgG was not done.
One year SLIT with D.pt extract was clinically efficient treatment in AR patients.

 
Keyword(s): ALLERGIC RHINITIS, ASTHMA, DERMATOPHAGOIDES PTERONYSSINUS, EFFICACY, SUBLINGUAL IMMUNOTHERAPY
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

VESNA, T., & DENISA, D., & SLAVENKA, J., & LIDIJA, B., & ALEKSANDRA, B., & JASNA, B., & VOJISLAV, D., & ALEKSANDRA, P., & ALEKSANDRA, A. (2016). EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH DERMATOPHAGOIDES PTERONYSSINUS: A REAL-LIFE STUDY. IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI), 15(2), 112-121. https://www.sid.ir/en/journal/ViewPaper.aspx?id=510319



Vancouver: Copy

VESNA TOMIC SPIRIC, DENISA DIZDAREVIC, SLAVENKA JANKOVIC, LIDIJA BURAZER, ALEKSANDRA BARAC, JASNA BOLPACIC, VOJISLAV DJURIC, ALEKSANDRA PERIC POPADIC, ALEKSANDRA ALEKSIC. EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH DERMATOPHAGOIDES PTERONYSSINUS: A REAL-LIFE STUDY. IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI). 2016 [cited 2021July29];15(2):112-121. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510319



IEEE: Copy

VESNA, T., DENISA, D., SLAVENKA, J., LIDIJA, B., ALEKSANDRA, B., JASNA, B., VOJISLAV, D., ALEKSANDRA, P., ALEKSANDRA, A., 2016. EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH DERMATOPHAGOIDES PTERONYSSINUS: A REAL-LIFE STUDY. IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI), [online] 15(2), pp.112-121. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510319.



 
  pdf-File
Yearly Visit 53
 
 
Latest on Blog
Enter SID Blog